• EXO-NET customer base growing across US, Europe and Asia
• Ovarian Cancer Screening test development progressing with exclusive licence for exosomal biomarkers
• CAR-exosome program demonstrates potent in vitro and in vivo anti-tumour activity

INOVIQ Limited (ASX:IIQ) reported a net loss of $3,958,678 for the half-year ended 31 December 2025, compared to a net loss of $3,653,953 in the prior corresponding period. The company made significant progress during the half-year, growing its EXO-NET customer base across the US, Europe and Asia, and delivering key development milestones across its exosome diagnostic and exosome therapeutic programs. INOVIQ secured an exclusive worldwide licence from The University of Queensland to develop and commercialise novel exosomal biomarkers for the early detection of ovarian cancer, and progressed sample acquisition for a larger clinical study to assess its EXO-OC test performance. The company also reported positive in vitro and in vivo proof-of-concept results for its CAR-NK-exosome therapeutic candidate, demonstrating potent anti-tumour activity against triple-negative breast cancer. INOVIQ completed a $10.2 million capital raise to accelerate development of its ovarian cancer test and therapeutic programs, and appointed experienced public company director Peter Gunzburg as Non-Executive Chairman. The company also appointed global exosome and cell therapy leader Dr Rebecca Lim as Chief Scientific Officer.

INOVIQ did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

INOVIQ is focused on executing its strategy and delivering on key milestones for its exosome-based diagnostics and therapeutics pipeline. With secured funding and key personnel in place, the company is well-positioned to achieve value inflections that will create value for patients, partners, and investors.